

Carbohydrate Research 305 (1998) 293-303

CARBOHYDRATE RESEARCH

4,6-Di-*O*-benzoyl-3-*O*-benzyl- α -D-*arabino*-hexopyranos-2-ulosyl bromide: A conveniently accessible glycosyl donor for the expedient construction of diantennary β -D-mannosides branched at O-3 and O-6

Frieder W. Lichtenthaler^{a.*}, Ulrich Kläres^a, Zoltán Szurmai^b, Bernd Werner^a

 ^a Institut für Organische Chemie, Technische Universität Darmstadt, Petersenstraße 22, D-64287 Darmstadt, Germany
^b Institute of Biochemistry, L. Kossuth University, P.O.B. 55, H-4010 Debrecen, Hungary

Received 6 May 1997; accepted 1 August 1997

Abstract

A concise practical, large scale-adaptable six-step sequence has been developed for the transformation of diacetone-glucose into 4,6-di-*O*-benzoyl-3-*O*-benzyl- α -D-*arabino*-hexo-pyranos-2-ulosyl bromide (7), a most useful indirect β -D-mannosyl donor as its blocking group pattern allows the construction of biologically relevant β -D-mannosides branched at O-3 and O-6. The broad utility of this new ulosyl bromide 7 resides in its high anomeric reactivity, and in the ease and uniformity with which β -stereocontrol can be achieved over both, glycosidations and carbonyl reduction of the β -ulosides formed: Koenigs–Knorr conditions exclusively provide β -glycosiduloses, hydride reduction of their carbonyl functions proceeds with high stereoselectivities (> 20:1) in favor of the β -D-mannosides. These preparatively auspicious properties are materialized in an efficient, straightforward synthesis of α -D-Manp-(1 \rightarrow 6)-[α -D-Manp-(1 \rightarrow 3)]- β -D-Manp-(1 \rightarrow *O*)-Octyl, the 3,6-O-branched core-mannotrioside carrying an octyl spacer instead of the chitobiosyl unit. © 1998 Elsevier Science Ltd

Keywords: β-D-Mannosides; β-D-Glycosid-2-uloses; Glycosidation: Mannotrioside; Oligosaccharide synthesis

1. Introduction

Of the numerous strategies developed for the construction of β -D-mannosidic linkages [1], the *in*- tramolecular aglycon delivery method [2–4] and the ulosyl bromide approach [5–11] have performed particularly well with respect to the β -selectivities attainable in the crucial glycosidation step. In both cases, the underlying reasons for the essentially complete β -stereocontrol are the same: practically full

[©] Corresponding author.

^{0008-6215/98/\$19.00 © 1998} Elsevier Science Ltd All rights reserved. *PII* \$0008-6215(97)00249-8



Scheme 1. Anomeric stereocontrol involved in the intramolecular aglycon delivery (I) [2–4] and the ulosyl bromide approach (II) [5–10] for the generation of β -D-mannosidic linkages.

suppression of oxocarbenium ion formation following anomeric activation of the mannosyl donor. In the intramolecular aglycon delivery protocol, this is accomplished by covalent pre-attachment of the saccharidic acceptor to O-2 of a latent mannosyl donor, which entails a concerted reaction of the type depicted in I. In the procedure involving 2-oxo-glycosyl ('ulosyl') bromides of type II as indirect β -D-mannosyl donors, the stereocontrol relies on the electron withdrawing effect of the 2-keto group which favors direct S_N2 displacement of the anomeric substituent by the alcohol component to such an extent that β -D-glycosiduloses are obtained exclusively (Scheme 1).

Aside from the essential β -specificity attainable in the insoluble silver salt-promoted glycosidation step, ulosyl bromides have the preparative advantage to be nearly as well accessible from glucose ($\rightarrow 1-3$ [5,8,9]), cellobiose ($\rightarrow 4$ [6]), or lactose ($\rightarrow 5$ [6]), as the respective glycosyl bromides. Key intermediates for the four steps required are their 2-acyloxy-glycal esters or ethers, which simply by exposure to *N*bromosuccinimide/methanol provide the ulosyl bromides in 80–90% yields [5–9]. An alternate protocol from 2-acyloxy-glycals to ulosyl bromides comprises the three-step sequence hydroxylaminolysis $[12] \rightarrow$ deoximation \rightarrow anomeric photobromination [13], a protocol that, on replacement of the deoximation step by *O*-benzoylation of the oxime, can also be utilized for the acquisition of the 2-benzoximino analogs of **1–6** [6–8,13] which have proven to be highly useful indirect β -D-mannosaminyl donors [14–17] (Scheme 2).

The other key parameter of this ulosyl bromide approach concerns the degree of manno-selectivity achievable on hydride reduction of the 2-keto group in the β -D-glucosiduloses obtained on β -specific glycosidation of 1–6. The β -D-mannosides invariably are the major products, yet there seems to be a peculiar dependence of the manno / gluco ratio obtained on the nature of the 3-O-blocking group: 2:1 to 5:1 in favor of the β -D-mannosides in cases with 3-O-acyl moieties versus preparatively satisfactory 20:1 to 50:1 ratio, when the 3-oxygen, vicinal to the carbonyl function, is protected by a benzyl residue. Due to these favorable assets, and the fact that the β -D-mannosides accumulate with a free 2-OH group suited for introduction of other glycosyl residues, the benzylated ulosyl bromide 6 has been successfully applied to the synthesis of a fairly complex trisaccharide unit of the Hyriopsis schlegelii glycosphingolipid [10] and of a physiologically active fungal metabolite [11].

For broadening the scope of ulosyl bromides as indirect β -D-mannosyl donors, it appeared indispensable to provide analogs with a blocking group pattern allowing for glycosylations at O-3 and O-6 in order to address synthetically the core structure of highmannose-type glycoproteins. These requirements are met by the 3-O-benzyl-4,6-di-O-benzoyl protected ulosyl bromide 7, whose straightforward acquisition from diacetone-glucose is described in this paper,



Scheme 2. The ulosyl bromide approach [5–10] for the generation of β -D-mannopyranosides. Piv: pivaloyl (*t*BuCO); β Bz₄Glc: 2,3,4,6-tetra-O-benzoyl- β -D-glucopyranosyl; β Bz₄Gal: 2,3,4,6-tetra-O-benzoyl- β -D-galactopyranosyl).





Scheme 3.

together with its utilization for the synthesis of O^3 , O^6 -branched β -D-mannosides, e.g. the core-trisaccharide **8** of high-mannose-type oligosaccharides carrying an octyl spacer instead of the chitobiosyl moiety (Scheme 3).

2. Results and discussion

For the acquisition of the title ulosyl bromide 7, with a benzyl group at O-3 and benzoyl groups at O-4 and O-6, an expedient six-step reaction sequence was elaborated starting from diacetone-glucose, which allows for a quite satisfactory overall yield of 49%. In the first three steps it involved adaption of published procedures to the 20 g scale, i.e. 3-O-benzylation $(9 \rightarrow 10 [18])$, removal of the isopropylidene groups by treatment with a strongly acidic resin [19], and benzoylation of the resulting 3-O-benzyl-D-glucose $(11 \rightarrow 12)$ [23] (Scheme 4). The conversion of tetrabenzoate 12 into its α -bromide 13 by exposure to hydrogen bromide/acetic acid and the subsequent base-induced elimination of hydrogen bromide was readily performed in one continuous operation, to afford the 2-benzoyloxy-glucal 14 in 80% yield for the two steps. The transformation of 14 into ulosyl bromide 7 was effected by brief exposure to Nbromosuccinimide/ethanol in dichloromethane (10 min, 0 °C) which smoothly and nearly quantitatively generated the desired ulosyl bromide 7; it was characterized as a uniform syrup of the expected positive rotation ([α]_D²⁰ + 103.7°), which surprisingly is only half of the rotational value obtained for its fully benzovlated analog **2** (+208° [13]).

Glycosidations of ulosyl bromide 7 under the Koenigs-Knorr-type conditions used previously [8–10], i.e. silver carbonate/dichloromethane at room temperature, proceeded in essentially β -specific manner and were completed within minutes: isopropanol gave the glycosidulose **15** in 95% yield, isolable either as an approximate 10:1 mixture of its 2-keto and 2,2-dihydroxy (monohydrate) forms, or as the pure monohydrate, depending on the mode of crystallization — a behaviour not unexpected in view of analogous previous observations [20]; reaction of **7** with 1,2:3,4-diacetone-galactose (\rightarrow **16**, 80%) and with *n*-octanol (\rightarrow **17**, 77%) proceeded as readily, again affording the β -D-glycosiduloses as crystalline mixtures of the 2-keto and monohydrate forms.



Scheme 4.

 β -D-Glycosiduloses with a benzyl protecting group at O-3 have been shown to provide particularly high *manno*-selectivities on hydride reduction (20:1 to 50:1 [9]). Thus, not unexpectedly, the same degree of stereoselection was observed in the sodium borohydride reductions of ulosides 15–17 affording the respective β -D-mannosides 18–20 in average yields of 80%.

Comparing the performance of ulosyl bromide 7 as an indirect β -D-mannosyl donor with that of its perbenzylated analog 6 [9], it is apparent that the two benzoyl ester functionalities at O-4 and O-6 have little if any effect on the high anomeric reactivity of 7 as well as on the steric course of the glycosidation, as both proceed with similar ease and in β -specific fashion. That, in addition, *manno*-selectivities of > 20:1 are obtained in the uloside reduction step (15–17 \rightarrow 18–20) renders ulosyl bromide 7 with its differentiated blocking group pattern a most versatile donor for the generation of β -D-mannosides not only ramified at O-2—a free 2-OH group already emerges from the reaction sequence—but at O-3 and O-6 as well through simple blocking group manipulations.

To probe the utility of this ulosyl bromide for the synthesis of the O-3,6-branched diantennary coremannotrioside type, the suitably blocked octyl β -Dmannoside **20**, readily accessible from **7** in two highyielding steps (overall yield: 74%), was subjected to α -mannosylations at O-3 and/or O-6, respectively. Accordingly, upon 2-O-benzoylation (**20** \rightarrow **21**), the



Scheme 5.

hydroxyl functions at C-4 and C-6 were liberated by selective Zemplén de-O-benzoylation $(21 \rightarrow 22)$, or alternately O-3 was deblocked by hydrogenolysis of the 3-O-benzyl group $(20 \rightarrow 23)$ —manipulations, that were readily effected in preparatively satisfactory yields and led to nicely crystalline products (Scheme 5).

The α -mannosylation of the 3-OH-free octyl β -Dmannoside 23 was either carried out with acetobromo-mannose (24) under modified Helferich conditions (mercury(II) bromide in dichloromethane) or with 2,3,4,6-tetra-O-acetyl- α -D-mannopyranosyl trichloroacetimidate (25) by trimethylsilyl triflate promotion, to smoothly provide Man- $\alpha(1 \rightarrow 3)$ -Man- β -OOct **28** in acylated form (76%). Deblocking was smoothly achieved in one step to give the free dimannoside 29 (88%). In similar fashion, the octyl 2-Obenzoyl-3-O-benzyl- β -D-mannoside 22 could be regioselectively 6-O-mannosylated with 24 and mercury(II) bromide in dichloromethane, setting the stage - upon acetylation $26 \rightarrow 27$ — to liberation of the 3-OH junction in the central mannose residue by hydrogenolysis $(27 \rightarrow 30)$, and its trimethylsilyl triflate induced α -mannosylation with trichloroacetimidate 25: the fully acylated mannotrioside 32 was thus obtained (73%), and was readily deblocked under Zemplén conditions to yield the desired octyl 3,6-di-O-(α -D-mannosyl)- β -D-mannoside 8.

By way of summation, the easy accessibility (49% overall yield for the six steps from diacetone-glucose), the differentiated blocking group pattern, and the high anomeric reactivity render the 4,6-di-O-benzoyl 3-O-benzyl-protected ulosyl bromide 7 a most versatile indirect β -D-mannosyl donor with which O-3,6-diantennary as well as O-2,3,6-triantennary mannooligosaccharides may advantageously be assembled.

3. Experimental

General methods.—¹H (300 MHz) and ¹³C (75 MHz) NMR spectra were recorded at 25 °C with a Bruker AC 300 spectrometer. Chemical shifts (δ) are given in ppm relative to the signal for internal Me₄Si (CDCl₃). Column chromatography was performed on Kieselgel 60 (Merck, 230 mesh) and fractions were monitored by TLC on Kieselgel 60 F₂₅₄ (Merck) by detection with UV light and then charring with H₂SO₄. Optical rotations were measured for solutions in CHCl₃ at 20 °C with a Perkin Elmer 241 polarimeter, using a 10 cm/1 mL cell.

3-O-Benzyl-1, 2:5, 6-di-O-isopropylidene - α -Dglucofuranose (10).—A solution of 1,2:5,6-di-O-isopropylidene- α -D-glucofuranose (9) (18.0 g, 69 mmol) in dry tetrahydrofuran (80 mL) was added dropwise to a suspension of NaH (1.9 g, 76.5 mmol) and tetrabutylammonium iodide (200 mg, 0.5 mmol) in dry tetrahydrofuran (50 mL) at 0 °C. The mixture was allowed to warm up to room temperature then benzyl bromide (9 mL, 76 mmol) added, and the solution was at 50 °C for 2 h. MeOH (40 mL) was added and the mixture was further stirred for 2 h before cooling, filtering through Celite and concentrating. The residue was dissolved in CH₂Cl₂ (250 mL), the solution washed with water $(2 \times 100 \text{ mL})$, dried (Na_2SO_4) , and concentrated to a syrup which was distilled in a Kugelrohr: 21.1 g (87%) of **10**; bp 147 °C/0.05 torr; $[\alpha]_{D}^{20} - 26.4^{\circ}$ (c 1.2, CHCl₃); lit.: bp 165–169 $^{\circ}C/0.02$ torr [21]; $[\alpha]_{D}^{20} - 29.8 \ ^{\circ}C$ (c 1.0, CHCl₃) [18]; ¹H NMR (300 MHz, CDCl₃): δ 1.30, 1.36, 1.42, and 1.48 (4 s, each 3 H, 4 CH₃), 3.99 (dd, 1 H, H-6a), 4.01 (d, 1 H, H-3), 4.11 (dd, 1 H, H-6b), 4.14 (dd, 1 H, H-4), 4.36 (dt, 1 H, H-5), 4.57 (d, 1 H, H-2), 4.62 and 4.67 (2d, each 1 H, $CH_2C_6H_5$), 5.88 (d, 1 H, H-1), 7.30–7.34 (m, 5 H, C_6H_5); $J_{1,2} = 3.7$, $J_{3,4} = 3.2, J_{4,5} = 7.7, J_{5,6} = 6.0, J_{5,6b} = 6.1, J_{6,6} = 8.6, J_{BnCH2} = 11.8 \text{ Hz}; {}^{13}\text{C} \text{ NMR} (75.5 \text{ MHz}, \text{CDCl}_3):$ δ 25.4, 26.3, 26.8, and 26.9 (CH₃), 67.4 (C-6), 72.4 (CH₂C₆H₅), 72.6 (C-5), 81.4 (C-4), 81.8 (C-3), 82.7 (C-2), 105.3 (C-1), 109.4, and 111.8 (C(CH₃)₂), 127.6–137.7 (C₆H₅).

1, 2, 4, 6 - Tetra - O - benzoyl - 3 - O - benzyl - β - D glucopyranose (12).—A solution of 10 (16.2 g, 46 mmol) in water (80 mL) was stirred with Dowex 50 resin (H⁺ form, 30 g) for 2 h at 70 °C. Thereupon, the resin was filtered off, the filtrate was taken to dryness and the syrupy residue was crystallized from EtOAc (100 mL) to yield 10.1 g (81%) of 3-O-benzyl- α , β -D-glucopyranose (11) as a 1:1 α/β -anomeric mixture (¹H NMR), mp 132–134 °C, lit. 132–134 °C [22]. The product (10.0 g, 37 mmol) was dissolved in pyridine / CHCl₃ (100 mL each) and benzoyl chloride (21.5 mL, 185 mmol) was added. After stirring for 24 h at room temperature the mixture was diluted with CHCl₃ (200 mL), washed with 2 M HCl (4×100 mL), aq NaHCO₃, and water (100 mL), and dried (Na_2SO_4) . Evaporation of the solvent and dissolution of the residue in MeOH resulted in crystallization on cooling: 23.2 g (91%) of 12; mp 210-212 °C, lit. 209–210 °C [23]; $[\alpha]_D^{20} + 0.3^\circ$ (*c* 1.1, CHCl₃), lit. 0° (c 0.8, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 4.21 (t, 1 H, H-3), 4.25-4.30 (m, 1 H, H-5), 4.45 (dd, 1 H, H-6a), 4.61-4.65 (m, 1 H, H-6b), 4.65 (bs, 2 H, CH₂C₆H₅), 5.72 (dd, 1 H, H-4), 5.74 (dd, 1 H, H-2), 6.19 (d, 1 H, H-1), 6.98–8.03 (m, 25 H, 5 C₆H₅); $J_{1,2} = 7.7$, $J_{2,3} = J_{3,4} = 8.6$, $J_{4,5} \approx 9.3$, $J_{5,6a} \approx 5.1$, $J_{5,6b} = 3.2$, $J_{6a,b} = 12.2$ Hz; ¹³C NMR (75.5 MHz, CDCl₃): δ 63.0 (C-6), 70.4 (C-4), 72.1 (C-2), 73.1 (C-5), 74.2 (CH₂C₆H₅), 79.2 (C-3), 92.6 (C-1), 127.8–133.7 (5 C₆H₅), 164.8, 165.0, and 166.2 (COC₆H₅).

1,5-anhydro-2,4,6-tri-O-benzoyl-3-O-benzyl-Darabino-hex-1-enitol (14).—A solution of 12 (5.0 g, 7.3 mmol) in CH_2Cl_2 (50 mL) was treated with hydrogen bromide in HOAC (33%, 25 mL, 141 mmol) at 0 °C. The mixture was stirred for 10 min, diluted with ice-cold CH_2Cl_2 (150 mL), washed with ice water, ice-cold aqueous NaHCO₃ (3×50 mL), water (50 mL), then dried (Na_2SO_4) . The solvent was evaporated, the residue consisting of crude 13, was dissolved in CH_2Cl_2 (60 mL), and DBU (1.4 mL, 9.5 mmol) was added. After 1.5 h stirring at room temperature the solution was washed with 2 M HCl $(3 \times 50 \text{ mL})$ and water (50 mL), dried (Na_2SO_4) and concentrated. The residual syrup was purified by elution from a short column of silica gel with CH_2Cl_2 , to yield on evaporation of the respective eluate 3.28 g of 14 (80%) as a hard foam; $[\alpha]_{D}^{20} - 4.4^{\circ}$ (c 1, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 4.41 (dd, 1 H, H-6a), 4.72 (bs, 2 H, BnCH₂), 4.77 (ddd, 1 H, H-5), 4.85 (dd, 1 H, H-6b), 5.69 (t, 1 H, H-4), 6.83 (s, 1 H, H-1), 7.06–8.11 (m, 20 H, 4 C₆H₅); $J_{3.4} = J_{4.5} = 3.5$, $J_{5,6a} = 3.4$, $J_{5,6b} = 7.6$, $J_{6a,b} = 11.4$ Hz; ³C NMR (75.5 MHz, CDCl₃): δ 62.0 (C-6), 68.4 (C-4), 70.8 (C-3), 71.7 (CH₂C₆H₅), 74.3 (C-5), 127.8– 133.7 (4 C₆H₅), 129.7 (C-2), 138.0 (C-1), 165.4, 165.6, and 166.3 (COC_6H_5). MS (FD/20 mA): m/z564 [M⁺], 565 [M⁺+1]. Anal. Calcd for $C_{34}H_{28}O_8$ (564.56): C, 72.33; H, 5.00. Found: C, 72.19; H, 4.93.

4, 6 - Di - O - benzoyl - 3 - O - benzyl - α - D - arabinohexopyranos - 2-ulosyl bromide (7). --- To a cooled (0 °C) solution of 2-benzoyloxy-glucal **14** (1.1 g, 1.93 mmol) in CH₂Cl₂ (8 mL) was added EtOH (169 μ L, 2.9 mmol) and powdered molecular sieves (4 Å, 500 mg). After 10 min the mixture was treated with NBS (390 mg, 2.2 mmol) stirred for 30 min, then diluted with ice-cold CH₂Cl₂ (100 mL), successively washed with ice-cold ag 10% Na₂S₂O₃ solution (30 mL) and ice water (30 mL), dried (Na₂SO₄) and concentrated to give sirupy ulosyl bromide **7** (1.0 g, 96%); [α]²⁰_D + 103.7° (*c* 1, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 4.42 (dd, 1 H, H-6a), 4.61 and 4.96 (BnCH₂), 4.64–4.69 (m, 1 H, H-5), 4.66 (dd, 1 H, H-6b), 4.94 (d, 1 H, H-3), 5.78 (t, 1 H, H-4), 6.41 (s, 1 H, H-1), 7.05–8.10 (m, 15 H, 3 C_6H_5); $J_{3,4} = J_{4,5} = 10.1$, $J_{5,6a} = 5.1$, $J_{5,6b} = 2.6$, $J_{6,6} = 13.1$ Hz; ¹³C NMR (75.5 MHz, CDCl₃): δ 61.8 (C-6), 69.6 (C-4), 73.1 (C-5), 73.7 (CH₂C₆H₅), 76.8 (C-3), 84.5 (C-1), 128.3-136.5 (3 C_6H_5), 164.6, and 166.1 (COC_6H_5), 193.7 (C-2). MS (FD/20 mA): m/z 538, 540 [M⁺]. Anal. Calcd for $C_{27}H_{23}O_7$ Br (539.39): C, 60.12; H, 4.30; Br, 14.81. Found: C, 59.80; H, 4.20; Br, 14.70.

Isopropyl 4,6-di-O-benzoyl-3-O-benzyl-β-D-arabinohexopyranosid-2-ulose (15).—A suspension of isopropanol (300 μ L, 3.9 mmol), Ag₂CO₃ (1.1 g, 4 mmol), molecular sieves (4 Å, 500 mg) and CH_2Cl_2 (10 mL) was stirred for 15 min at room temperature with the exclusion of moisture. Ulosyl bromide 7 (950 mg, 1.76 mmol) was added and stirring was continued for 5 min, followed by filtration through Celite with extensive washing of the filter cake with CH_2Cl_2 . The combined filtrate and washings were concentrated, the resulting residue was crystallized from Et₂O: 870 mg (95%) of an approximate 10:1 mixture (¹H NMR) of 15 and its monohydrate (15 \cdot H₂O); mp 130–135 °C; $[\alpha]_{D}^{20}$ –69.9° (c 0.96, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 1.24 (d, 3) H, CH₃), 1.29 (d, 3 H, CH₃), 4.06 (qq, 1 H, CHMe₂), 4.29 (ddd, 1 H, H-5), 4.31 (d, 1 H, H-3), 4.51 (dd, 1 H, H-6a), 4.59 and 4.93 (BnCH₂), 4.63 (dd, 1 H, H-6b), 4.98 (s, 1 H, H-1), 5.67 (dd, 1 H, H-4), 7.14–7.98 (m, 15 H, 3 C_6H_5); $J_{3,4} = 9.3$, $J_{4,5} = 9.0$, $J_{5,6a} = 6.1, J_{5,6b} = 3.8, J_{6a,b} = 12.1, J_{CHMe2} = 6.2, J_{BnCH2} = 12.3 \text{ Hz;} {}^{13}\text{C NMR} (75.5 \text{ MHz, CDCl}_3): \delta$ 22.0, and 23.4 (CH₃), 64.2 (C-6), 81.1 (C-3), 98.3 (C-1), 128.2-137.1 (3 C₆H₅), 165.0, and 166.3 (COC_6H_5) , 197.0 (C-2); $J_{C-1,H-1} = 159$ Hz. Anal. Calcd for $C_{30}H_{30}O_8$ (518.6): C, 69.49; H, 5.83. Found: C, 69.33; H, 5.93.

Several recrystallisations from Et₂O/EtOAc yielded colorless crystals of the monohydrate (15. H₂O): mp 145–147 ⁰C; $[\alpha]_{D}^{20}$ – 58.8° (c 1.05, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 1.24 (d, 3 H, CH₃), 1.31 (d, 3 H, CH₃), 3.11, and 3.92 (2 bs, 2 H, 2 OH), 3.79 (d, 1 H, H-3), 3.88-3.95 (m, 1 H, H-5), 4.03 (qq, 1 H, CHMe₂), 4.39 (dd, 1 H, H-6a), 4.52 (s, 1 H, H-1), 4.53 (dd, 1 H, H-6b), 4.77 and 4.88 (2d, each 1 H, BnCH₂), 5.42 (t, 1 H, H-4), 7.05–7.96 (m, 15 H, 3 C₆H₅); $J_{3,4} = J_{4,5} = 9.7$, $J_{5,6a}$ = 6.1, $J_{5,6b} = 3.4$, $J_{6a,b} = 11.9$, $J_{CHMe2} = 6.2$, J_{BnCH2} = 11.7 Hz; ¹³C NMR (75.5 MHz, CDCl₃): δ 21.8 and 23.3 (CH₃), 63.9 (C-6), 70.7 (C-4), 71.9 (C-5), 75.2 (CH₂C₆H₅), 80.6 (C-3), 93.8 (C-2), 100.4 (C-1), 128.0–137.3 (3 C_6H_5), 165.3, 166.2 (COC_6H_5); $J_{\rm C-1,H-1} = 159.3$ Hz.

Octyl 4,6-di-O-benzoyl-3-O-benzyl-β-D-arabino-

hexopyranosid-2-ulose (17).—Glycal 14 (6.0 g, 10.6 mmol) was treated like above to give ulosyl bromide 7, which was dissolved in CH_2Cl_2 (50 mL). Molecular sieves (4 Å, 2 g), silver carbonate (5.8 g, 21.2 mmol) and n-octanol (3.4 mL, 21.2 mmol) were added. The suspension was stirred for 15 min, filtered through Celite and concentrated to give an amorphous residue, which crystallized from *t*-butyl methyl ether: 5.4 g (87%) of 17 and its monohydrate $17 \cdot H_2O$ as an approximate 7:1 mixture (¹H NMR); mp 112-112.5 °C; $[\alpha]_{D}^{20}$ -49.4° (c 1.1, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 0.86 (t, 3 H, CH₃), 1.24–1.36 (m, 10 H, 5 octyl-CH₂), 1.61-1.68 (m, 2 H, OCH₂CH₂), 3.61 (dt, 1 H, OCH₂), 3.88 (dt, 1 H, OCH₂), 4.30 (ddd, 1 H, H-5), 4.32 (d, 1 H, H-3), 4.51 (dd, 1 H, H-6a), 4.59 and 4.93 (2 d, each 1 H, $BnCH_{2}$, 4.63 (dd, 1 H, H-6a), 4.98 (s, 1 H, H-1), 5.68 (dd, 1 H, H-4), 7.14–7.99 (m, 15 H, 3 C₆H₅); $J_{3,4} = 9.3, J_{4,5} = 9.1, J_{5,6a} = 5.9, J_{5,6b} = 3.8, J_{6a,b} = 3.8$ 12.0, $J_{CH2,CH3} = 6.6$, $J_{OCH2,CH3} = 6.8$, $J_{OCH2} = 9.4$, $J_{BnCH2} = 12$. Hz; ¹³C NMR (75.5 MHz, CDCl₃): δ 14.5 (CH₃), 23.0, 26.2, 29.6, 29.7, 29.8, and 32.2 (CH₂), 64.3 (C-6), 70.6 (OCH₂), 72.9 (C-4), 73.2 (CH₂C₆H₅), 73.4 (C-5), 81.3 (C-3), 98.5 (C-1), 124.5–135.9 (3 C₆H₅), 165.0, and 166.3 (COC₆H₅), 197.0 (C-2); $J_{C-1,H-1} = 159.9$ Hz. Anal. Calcd for C₃₅H₄₀O₈ (588.7): C, 71.41; H, 6.85. Found: C, 71.23; H, 6.96.

The monohydrate portion of **17** exhibited substantially different chemical shifts for H-1 (s at δ 4.46) and H-3 (d at 3.79), and, less pronounced, for H-4 (dd at 5.45). ¹³C NMR (75.5 MHz, CDCl₃): δ 70.5 (C-5), 71.1 (C-6), 71.8 (C-4), 75.1 (CH₂C₆H₅), 80.3 (C-3), 93.7 (C-2), 101.7 (C-1).

Isopropyl 4, 6 - di - O - benzoyl - 3 - O - benzyl - β - D mannopyranoside (18).—NaBH₄ was added to a stirred, cooled (0 °C) solution of 15 (1.0 g, 1.93 mmol) in 33 mL of 10:1 dioxane/water and stirring was continued for 20 min, allowing the mixture to warm up to room temperature; HOAc (0.5 mL) was added and the solution was diluted with acetone, filtered through a silical gel short bed and concentrated in vacuo. Crystallization from Et_2O/n -hexane gave 840 mg (84%) of mannoside 18; mp 127-129 °C; $[\alpha]_D^{20} - 45.4^\circ$ (c 1.1, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 1.19, and 1.27 (2 d, each 3 H, 2 CH₃), 2.60 (d, 1 H, OH), 3.71 (d, 1 H, H-3), 3.85 (ddd, 1 H, H-5), 4.05 (qq, 1 H, CHMe₂), 4.15 (bs, 1 H, H-2), 4.44 (dd, 1 H, H-6a), 4.57 and 2.72 (2d, each 1 H BnCH₂), 4.58 (dd, 1 H, H-6b), 4.65 (d, 1 H, H-1), 5.66 (t, 1 H, H-4), 7.17-8.05 (m, 15 H, 3 C_6H_5 ; $J_{1,2} \approx 1.0$, $J_{2,OH} = 2.1$, $J_{2,3} = 3.2$, $J_{3,4} = J_{4,5}$ = 9.3, $J_{5,6a} = 6.2$, $J_{5,6b} = 3.7$, $J_{6a,b} = 11.8$, $J_{CHMe2} = 6.2$, $J_{BnCH2} = 12.4$ Hz; ¹³C NMR (75.5 MHz, CDCl₃): δ 21.8, and 23.5 (CH₃), 64.2 (C-6), 68.4 (C-2), 69.0 (C-4), 71.2 ($CH_2C_6H_5$), 71.8 ($CHMe_2$), 72.1 (C-5), 77.9 (C-3), 98.1 (C-1), 127.9-137.4 (3 C₆H₅), 165.5, and 166.3 (COC_6H_5). Anal. Calcd for C₃₀H₃₂O₈ (520.6): C, 69.22; H, 6.20. Found: C, 69.24; H, 6.13.

1,2:3,4-Di-O-isopropylidene-6-O-(4,6-di-O-benzoyl-3-O-benzyl- β -D-mannopyranosyl)- α -D-galactopyranose (19).—A suspension of 1,2:3,4-di-O-isopropylidene- α -D-galactopyranose (440 mg, 1.70 mmol), silver carbonate (980 mg, 3.50 mmol), and molecular sieves (3 Å, 500 mg) in CH_2Cl_2 (5 mL) was stirred for 10 min at room temperature. A solution of ulosyl bromide 7 (955 mg, 1.77 mmol, in CH_2Cl_2 (15 mL) was added dropwise with stirring, and after 20 min the mixture was filtered through Celite and concentrated. The syrupy residue consisted (¹H NMR) of β -uloside 16 and its monohydrate in an approximate 5:1 ratio, and was directly subjected to reduction: dissolution in 10:1 dioxane-water (33 mL), cooling at 0 °C and stirring with NaBH₄ (68 mg, 1.8 mmol) for 20 min. The mixture was then allowed to warm up to room temperature, and HOAc (0.5 mL) was added followed by dilution with acetone and concentration. Purification of the residue by elution from a silica gel column with 1:1 toluene-EtOAc afforded 19 (945 mg, 77%, based on 7) as a colorless syrup; $[\alpha]_{D}^{20} - 58.3^{\circ}$ (c 1.0, CHCl₃); ¹H NMR (300 MHz, CDCl₃): mannosyl-H: δ 2.79 (bs, 1 H, OH), 3.69 (dd, 1 H, H-3), 3.85 (ddd, 1 H, H-5), 4.30 (m, 1 H, H-2), 4.45 (dd, 1 H, H-6a), 4.55 and 4.71 (2 d, each 1 H, BnCH₂), 4.58 (dd, 1 H, H-6b), 4.71 (d, 1 H, H-1), 5.71 (t, 1 H, H-4), 7.15–8.00 (m, 15 H, 3 C_6H_5); $J_{1,2} \approx 1.0, \quad J_{2,3} = 3.1, \quad J_{3,4} = J_{4,5} = 9.2, \quad J_{5.6a} = 5.6,$ $J_{5.6b} = 3.7$, $J_{6a,b} = 11.9$, $J_{BnCH2} = 12.4$ Hz; galacto*syl-H*: δ 1.29, 1.33, 1.41, and 1.53 (4 s, each 3 H, 4 CH₃), 3.77 (dd, 1 H, H-6a), 4.04–4.07 (m, 1 H, H-5), 4.10 (dd, 1 H, H-6b), 4.15 (dd, 1 H, H-4), 4.30 (dd, 1 H, H-2), 4.53-4.61 (m, 1 H, H-3), 5.55 (d, 1 H, H-1); $J_{2,3} = 2.5$, $J_{3,4} = 7.9$, $J_{4,5} = 1.6$, $J_{5.6a} = 7.7$, $J_{5.6b} = 2.6$, $J_{6a,b} = 11.1$ Hz; ¹³C NMR (75.5 MHz, CDCl₃): mannosyl-C: δ 64.2 (C-6), 67.8 (C-2), 68.4 (C-4), 71.3 $(CH_2C_6H_5)$, 72.5 (C-5), 77.9 (C-3), 100.7 (C-1), 128.1–133.4 (3 C₆H₅), 165.6, and 166.4 (COC₆H₅); galactosyl-C: δ 24.6, 25.2, 26.2, 26.3 (CH₃), 69.0 (C-5), 69.6 (C-6), 70.7 (C-2), 70.9 (C-3), 71.6 (C-4), 96.5 (C-1). Anal. Calcd for $C_{30}H_{44}O_{13}$ (720.8): C, 64.99; H, 6.15. Found: C, 65.09; H, 6.04.

Octyl 4, 6 - di - O - benzoyl - 3 - O - benzyl - β - D - mannopyranoside (20).—Subjection of 17 (950 mg,

1.6 mmol) to reduction with NaBH₄ (64 mg, 1.7 mmol) in 10:1 dioxane-water (33 mL), and processing of the mixture as described for $15 \rightarrow 18$ yielded 805 mg (85%) of **20** as colorless needles; mp 111–113 °C; $[\alpha]_{\rm D}^{20} - 32.4^{\circ} (c \ 1, \text{CHCl}_3)$; ¹H NMR (300 MHz, CDCl₃): δ 0.87 (t, 3 H, CH₃), 1.26–1.76 (m, 12 H, 6 CH₂), 2.58 (d, 1 H, OH), 3.52 (dt, 1 H, OCH₂), 3.72 (dd, 1 H, H-3), 3.83–3.96 (m, 2 H, H-5, and OCH₂), 4.19 (s, 1 H, H-2), 4.47 (dd, 1 H, H-6a), 4.57 (s, 1 H, H-1), 4.58 and 4.71 (2 d, each 1 H, BnCH₂), 4.59 (dd, 1 H, H-6b), 5.68 (t, 1 H, H-4), 7.14-8.00 (m, 15 H, 3 C₆H₅); $J_{2,OH} = 2.3$, $J_{2,3} = 3.1$, $J_{3,4} = J_{4,5} = 9.1$, $J_{5,6a} = 5.9, J_{5,6b} = 3.8, J_{6a,b} = 11.8, J_{CH2,CH3} = 6.8, J_{OCH2,CH2} = 6.9, J_{OCH2} = 9.3, J_{BnCH2} = 12.4$ Hz; ¹³C NMR (75.5 MHz, CDCl₃): δ 14.1 (CH₃), 22.6, 26.0, 29.2, 29.3, 29.5, and 31.8 (CH₂), 64.0 (C-6), 67.9 (C-2), 68.9 (C-4), 70.1 (OCH₂), 71.3 ($CH_2C_6H_5$), 72.1 (C-5), 77.8 (C-3), 99.9 (C-1), 127.8-137.3 (3 C_6H_5), 165.4, and 166.2 (COC_6H_5). Anal. Calcd for C₃₅H₄₂O₈ (590.7): C, 71.17; H, 7.17. Found: C, 71.03; H, 6.97.

Octyl 2, 4, 6 - tri - O - benzoyl - 3 - O - benzyl - β - D mannopyranoside (21).—Benzoyl chloride (380 μ L, 3.3 mmol) was added to a stirred solution of 20 (1.3 g, 2.2 mmol) in pyridine (30 mL). After 1 h the mixture was diluted with CH₂Cl₂ (100 mL), and was washed successively with 2 M HCl (2×30 mL). After drying (Na_2SO_4) , the solvent was evaporated, and the residue was crystallized from EtOH: 1.36 g (89%) of **21**; mp 101–102 °C; $[\alpha]_{D}^{20} - 110^{\circ}$ (c 1, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 0.84 (t, 3) H, CH₃), 1.17–1.56 (m, 12 H, 6 CH₂), 3.51 (dt, 1 H, OCH₂), 3.82–3.86 (m, 1 H, OCH₂), 3.84 (dd, 1 H, H-3), 3.89–3.94 (m, 1 H, H-5), 4.44 (dd, 1 H, H-6a), 4.53 and 4.73 (2 d, each 1 H, BnCH₂), 4.66-4.71 (m, 1 H, H-6b), 4.71 (s, 1 H, H-1), 5.78 (dd, 1 H, H-4), 5.90 (d, 1 H, H-2), 7.07-8.14 (m, 20 H, 4 C_6H_5 ; $J_{2,3} = 3.3$, $J_{3,4} = 9.7$, $J_{4,5} = 9.8$, $J_{5,6a} = 5.1$, $J_{5.6b} = 2.9, J_{6a,b} = 12.0, J_{CH2,CH3} = 6.5, J_{OCH2,CH2} = 6.8, J_{OCH2} = 9.2, J_{BnCH2} = 12$ Hz; ¹³C NMR (75.5) MHz, CDCl₃): δ 14.2 (CH₃), 22.8, 25.9, 29.3, 29.4, 29.5, and 31.8 (CH₂), 63.6 (C-6), 68.1 (C-2), 68.7 (C-4), 70.1 (OCH₂), 70.5 (CH₂C₆H₅), 72.4 (C-5), 76.1 (C-3), 99.3 (C-1), 127.9-137.3 (4 C₆H₅), 165.4, 166.3, and 166.4 (COC_6H_5) . Anal. Calcd for C₄₂H₄₆O₉ (694.8): C, 72.60; H, 6.67. Found: C, 72.52; H. 6.75.

Octyl 3-O-benzyl- β -D-mannopyranoside (22 with Hinstead of Bz).—A solution of tribenzoate 21 (410 mg, 0.59 mmol) in MeOH (20 mL) was treated with NaOMe (25 mg, 0.46 mmol) and stirred for 2 h at room temperature. The resulting mixture was neutralized with an acidic resin (Dowex 50 WX 4, H⁺-form) followed by filtration, concentration of the filtrate and elution of the residue from a short silica gel column with 10:1 CHCl₃-MeOH. The major fraction was taken to a syrup that was chromatographically uniform: 205 mg (91%) of octyl 3-O-benzyl- β -Dmannoside, $[\alpha]_{D}^{20} - 61.1^{\circ} (c \ 1, \text{ CHCl}_{3}); ^{1}\text{H} \text{ NMR}$ (300 MHz, CDCl₃): δ 0.81 (t, 3 H, CH₃), 1.20–1.56 (m, 12 H, 6 CH₂), 2.75 (bs, 2 H, 2 OH), 3.02 (bs, 1 H, 1 OH), 3.19 (ddd, 1 H, H-5), 3.30 (dd, 1 H, H-3), 3.42 (dt, 1 H, OCH₂), 3.74–3.86 (m, 2 H, H-6a,b), 3.82 (dt, 1 H, OCH₂), 3.91 (dd, 1 H, H-4), 4.02 (bd, 1 H, H-2), 4.36 (d, 1 H, H-1), 4.52 and 4.71 (2 d, each 1 H, BnCH₂), 7.23-7.32 (m, 5 H, C₆H₅); $J_{1,2} = 0.4, J_{2,3} = 3.0, J_{3,4} = 9.3, J_{4,5} = 9.5, J_{CH2CH3}$ = 6.5, $J_{\text{OCH2,CH2}} = 6.9$, $J_{\text{OCH2}} = 9.5$ Hz; ¹³C NMR (75.5 MHz, CDCl₃): δ 14.2 (CH₃), 22.8, 26.1, 29.3, 29.5, 29.6, and 31.9 (CH₂), 62.4 (C-6), 66.6 (C-4), 68.0 (C-2), 70.2 (OCH₂), 71.3 (CH₂C₆H₅), 75.6 (C-5), 81.0 (C-3), 100.1 (C-1), 128.1–137.7 (C₆H₅). MS (FD/15 mA): m/z 382 [M⁺], 383 [M⁺+1], 384 $[M^++2]$. Anal. Calcd for $C_{21}H_{34}O_6$ (382.5): C, 65.94; H, 8.96. Found: C, 65.86; H, 8.87.

Octyl 2-O-benzoyl-3-O-benzyl-β-D-mannopyranoside (22).—A solution of tribenzoate 21 (1.1 g, 1.6 mmol) in MeOH (20 mL) and CH_2Cl_2 (5 mL) was cooled (0 °C) and NaOMe (85 mg, 1.6 mmol) was added. The reaction was monitored by TLC (1:1 toluene-EtOAc) being complete in terms of selective 4,6-di-debenzovlation after about 4.5 h. Subsequent neutralization with HOAc (3 mL), evaporation of the solution in vacuo to dryness and elution of the residue from a short silica gel column with CHCl₂acetone gave 740 mg (96%) of 22 as a chromatographically uniform, colorless syrup; $[\alpha]_{D}^{20} - 80.1^{\circ}$ (c 1, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 0.85 (t, 3 H, CH₃), 1.20–1.26 (m, 10 H, 5 CH₂), 1.53 (m, 2 H, OCH_2), 2.35 and 2.80 (2 bs, each 1 H, 2 OH), 3.41 (ddd, 1 H, H-5), 3.49 and 3.82 (2 dt, each 1 H, octyl-OCH₂), 3.55 (dd, 1 H, H-3), 3.88 (dd, 1 H, H-6a), 3.96 (dd, 1 H, H-6b), 3.97 (dd, 1 H, H-4), 4.45 and 4.84 (2 d, each 1 H, BnCH₂), 4.64 (bs, 1 H, H-1), 5.82 (bs, 1 H, H-2), 7.13-8.10 (m, 10 H, 2 C_6H_5), $J_{1,2} = 0.8$, $J_{2,3} = 3.0$, $J_{3,4} = J_{4,5} = 9.3$, $J_{5,6a} = 5.0$, $J_{5,6b} = 3.3$, $J_{6,6} = 11.9$ Hz; ¹³C NMR (75.5 MHz, CDCl₃): δ 14.1 (CH₃), 22.6, 25.9, 29.2, 29.3, 29.5, and 31.7 (CH₂), 62.7 (C-6), 67.4 (C-4), 68.0 (C-2), 70.1 (OCH₂), 71.2 (CH₂C₆H₅), 75.7 (C-5), 79.8 (C-3), 99.3 (C-1), 128.1–137.3 (2 C₆H₅), 166.1 (COC_6H_5) . MS (FD/20 mA): m/z 486 [M⁺], 487 $[M^++1]$, 488 $[M^++2]$. Anal. Calcd for $C_{28}H_{38}O_7$ (486.6): C, 69.11; H, 7.87. Found: C, 68.98; H, 7.81.

Octyl 2, 4, 6-tri-O-benzoyl- β -D-mannopyranoside (23).—A solution of mannoside 21 (350 mg, 0.5 mmol) in MeOH (20 mL) was hydrogenated in the presence of 10% palladium-carbon. After six days the suspension was filtered and concentrated in vacuo, followed by fast elution of the residue from a short silica gel column with (5:1) toluene-EtOAc⁻¹. The eluate containing 23 was concentrated to give 248 mg (82%) of a syrup; $[\alpha]_D^{20} - 55.1^\circ$ (c 1.1, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 0.84 (t, 3 H, CH₃), 1.15–1.55 (m, 12 H, 6 CH₂), 2.92 (d, 1 H, 1 OH), 3.53 (dt. 1 H, OCH₂), 3.85 (dt, 1 H, OCH₂), 4.04 (ddd, 1 H, H-5), 4.14-4.20 (m, 1 H, H-3), 4.52 (dd, 1 H, H-6a), 4.73 (dd, 1 H, H-6b), 4.82 (d, 1 H, H-1), 5.60 (t, 1 H, H-4), 5.69 (dd, 1 H, H-2), 7.35-8.11 (m, 15 H, 3 C₆H₅); $J_{1,2} = 1.1$, $J_{3,OH} = 6.8$, $J_{2,3} = 3.3$, $J_{3,4} = J_{4,5} = 8.9, J_{5,6a} = 5.4, J_{5,6b} = 3.3, J_{6a,b} = 11.9, J_{CH2,CH3} = 6.7, J_{OCH2,CH2} = 6.7, J_{OCH2} = 9.4$ Hz; ¹³C NMR (75.5 MHz, CDCl₃): δ 14.1 (CH₃), 22.6, 25.8, 29.2, 29.3, 29.4, and 31.7 (CH₂), 63.7 (C-6), 70.0 (OCH₂). 70.9 (C-4), 71.4 (C-3), 71.7 (C-2), 72.3 (C-5), 99.0 (C-1), 128.4–133.6 (3 C₆H₅), 166.2, 166.3, and 166.5 (COC_6H_5). MS (FD/15 mA): m/z604 [M⁺], 606 [M⁺+2]. Anal. Calcd for $C_{35}H_{40}O_{9}$ (604.7): C, 69.52; H, 6.69. Found: C, 69.39; H, 6.60.

Octyl 2-O-benzoyl-3-O-benzyl-6-O-(2,3,4,6-tetra-O $acetyl - \alpha - D - mannopyranosyl) - \beta - D - mannopyranoside$ (26).—A suspension of mannoside 22 (487 mg, 1 mmol), 2,3,4,6-tetra-O-acetyl- α -D-mannopyranosyl bromide 24 (1.23 g, 3 mmol), and powdered molecular sieves (4 Å, 500 mg) in CH₂Cl₂ (15 mL) was stirred under an atmosphere of argon for 15 min; mercury(II) bromide (360 mg, 1 mmol) was added, following by stirring at room temperature for 24 h. The mixture was then diluted with CH₂Cl₂, filtered and successively washed with aq 5% potassium iodide solution (2 \times 20 mL) and water (2 \times 25 mL), dried (Na_2SO_4) and concentrated to a syrup, which consisted of an approximate 10:1 mixture (¹H NMR) of 26 and the α -(1 \rightarrow 4)-linked disaccharide. Elution of this syrup from a silica gel column with CH₂Cl₂-EtOAc $(9:1 \rightarrow 3:1 \text{ gradient})$ gave on concentration of the major fraction 700 mg (86%) of 26; ¹H NMR (300 MHz, CDCl₃): β -mannosyl-H: δ 0.85 (t, 3 H, CH₃), 1.19–1.28 (m, 10 H, 5 CH₂), 1.52–1.56 (m, 2 H, OCH₂CH₂), 3.51 and 3.85 (2 dt, each 1 H, OCH₂C₇H₁₅), 3.48–3.57 (m, 2 H, H-3,5), 3.88 (bm, 1 H, H-6a), 3.92 (dd, 1 H, H-4), 4.01 (dd, 1 H, H-6b), 4.46 and 4.86 (2 d, each 1 H, $BnCH_2$), 4.64 (bs, 1 H, H-1), 5.85 (bd, 1 H, H-2), 7.2-8.1 (m, 10 H, 2 C₆H₅); $J_{1,2} > 0.5$, $J_{2,3} = 2.6$, $J_{3,4} = 9.4$, $J_{4,5} =$ 9.9, $J_{5.6a} = 3.8$, $J_{5.6b} = 5.7$, $J_{6a,b} = 10.7$ Hz; α -mannosyl-H: δ 2.00, 2.01, 2.07, and 2.16 (4 s, each 3 H, 4 Ac), 4.15 (dd, 1 H, H-6a), 4.14 (m, 1 H, H-5), 4.27 (dd, 1 H, H-6b), 4.91 (d, 1 H, H-1), 5.30 (dd, 1 H, H-4), 5.27–5.38 (m, 2 H, H-2,3), $J_{L2} = 1.1$, $J_{5.6a} = 2.2$, $J_{5.6b} = 5.6$, $J_{6a,b} = 12.6$ Hz; ¹³C NMR (75.5 MHz, CDCl₃): β-mannosyl-C: δ 14.0 (CH₃), 22.6, 25.8, 29.1, 29.3, 29.4, and 31.7 (OCH₂(CH₂)₆CH₃), 66.6 (C-6), 67.7 (C-2), 69.9 (CH₂C₇H₁₅), 71.1 $(CH_{2}C_{6}H_{5}), 74.7 (C-3), 80.0 (C-5), 99.1 (C-1),$ 128.1–137.1 (2 C₆H₅), 166.1 (COC_6H_5); α -mannosyl-C: 8 20.6, 20.7, and 20.8 (4 COCH₃), 62.3 (C-6), 66.0 (C-4), 68.4 (C-5), 69.1, and 69.4 (C-2, 3), 97.4 (C-1), 169.6, 169.7, 169.9, and 170.7 (4 $COCH_3$).

Octvl 4-O-acetyl-2-O-benzoyl-3-O-benzyl-6-O-(2,3,4, 6 - tetra - O - acetyl - α - D - mannopyranosyl) - β - D mannopyranoside (27).—Ac₂O (10 mL) was added to a solution of disaccharide **26** (700 mg) in pyridine (10 mL), and the mixture was stirred for 8 h at room temperature. The solution was taken to dryness in vacuo and the residue was purified by elution from silica gel column with 2:1 CH₂Cl₂-EtOAc. Concentration of the major fraction gave amorphous 27 (460 mg, 53%). Crystallization of an analytical sample from EtOH afforded fine needles; mp 118-119 °C; $[\alpha]_{D}^{20} - 35^{\circ}$ (c 1, CHCl₃). ¹H NMR (300 MHz, CDCl₃): β-mannosyl-H: δ 0.85 (t, 3 H, Ac), 1.19-1.27 (m, 10 H, 5 CH₂), 1.52–1.56 (m, 2 H, OCH₂CH₂), 2.15 (s, 3 H, COCH₃), 3.53 and 3.84 (2 dt, each 1 H, $OCH_2C_7H_{15}$), 3.56 and 3.86 (2 dd, 1 H, H-6a), 3.58 (bm, 1 H, H-5), 3.72 (dd, 1 H, H-3), 4.49 and 4.74 (2 d, each 1 H, BnCH₂), 4.66 (bs, 1 H, H-1), 5.16 (dd, 1 H, H-4), 5.84 (dd, 1 H, H-2), 7.23-8.10 (m, 10 H, 2 C₆H₅); $J_{1,2} > 0.5$, $J_{2,3} = 3.1$, $J_{3,4} = J_{4,5} = 9.7$, $J_{5,6a} = 2.8$, $J_{5,6b} = 3.6$, $J_{6,6} = 9.6$ Hz; α -mannosyl-H: δ 1.99, 2.01, 2.05, and 2.07 (4 s, each 3 H, 4 Ac), 4.11 (ddd, 1 H, H-5), 4.12 and 4.29 (2d, 1 H, H-6a), 4.83 (d, 1 H, H-1), 5.27 (dd, 1 H, H-2), 5.31 (dd, 1 H, H-3), 5.33 (bm, 1 H, H-4); $J_{1,2} = 1.6, J_{2,3} = 2.9, J_{3,4} = J_{4,5} = 9.7, J_{5,6} = 2.2$ and 5.6, $J_{6a,b} = 12.5$ Hz; ¹³C NMR (75.5 MHz, CDCl₃): β -mannosyl-C: δ 14.1 (CH₃), 21.2 (COCH₃), 23.6. 25.9, 29.2, 29.3, 29.4, and 31.7 (OCH₂(CH₂)₆CH₃), 67.4 (C-6), 68.2 (C-2), 68.6 (C-4), 69.9 (CH₂C₇H₁₅), 70.9 (*C*H₂C₆H₅), 72.9 (C-5), 76.6 (C-3), 98.9 (C-1),

¹ Exposure of **23** to silica gel should be kept at a minimum, as longer column chromatography (i.e. overnight) leads to substantial $2-O \rightarrow 3-O$ -benzoyl migration to give an approximate 1:1 mixture (¹H NMR) of **23** and octyl 3,4,6-tri-*O*-benzoyl- β -D-mannopyranoside.

127.8–137.5 (2 C_6H_5), 166.1 (COC_6H_5), 166.5 ($COCH_3$); α -mannosyl-C: δ 20.7, 20.7, 20.9, and 20.9 (4 $COCH_3$), 62.3 (C-6), 66.0 (C-4), 68.7 (C-5), 69.1 (C-2), 69.4 (C-3), 97.2 (C-1), 169.7, 169.8, 170.0, and 170.0 (4 $COCH_3$). MS (FD/20 mA): m/z 859 [M⁺+1], 858 [M⁺], 857 [M⁺-1], 856 [M⁺-2], 43 [CH₃CO⁺]. Anal. Calcd for $C_{44}H_{58}O_{17}$ (858.9): C, 61.53; H, 6.81. Found: C, 61.48; H, 6.73.

Octyl 2,4,6-tri-O-benzoyl-3-O-(2,3,4,6-tetra-O-acetyl - α - D - mannopyranosyl) - β - D - mannopyranoside (28).—A solution of 3-OH-free tribenzoate 23 (605 mg, 1 mmol) in CH_2Cl_2 (10 mL) was stirred with 2,3,4,6-tetra-O-acetyl- α -D-mannopyranosyl trichlorocetimidate (25) [21] and powdered molecular sieves (4 A, 1 g) in CH₂Cl₂ (10 mL) under argon for 30 min at room temperature, whereupon trimethylsilyl triflate (38.7 μ L, 1.15 mmol) was added dropwise. The mixture was stirred for 45 min at room temperature and guenched by the addition of pyridine (5 mL). Dilution with CH_2Cl_2 (40 mL), filtration through Celite, and successive washing with saturated aq NaHCO₃ (2 \times 10 mL), and water (2 \times 10 mL) gave upon drying (Na_2SO_4) and removal of the solvent in vacuo a syrup which was purified by elution from a silica gel column with CH_2Cl_2 -EtOAc (97:3 \rightarrow 95:5). Concentration of the eluate-containing product afforded 690 mg (76%) of 28 as an amorphous foam; $[\alpha]_{D}^{20} - 47.9^{\circ} (c \ 0.18, \text{CHCl}_{3});$ ¹H NMR (300 MHz, CDCl₃): δ 0.84 (t, 3 H, CH₃), 1.11–1.57 (m, 12 H, 6 CH₂), 1.82, 1.83, 2.00, and 2.11 (4 s, each 3 H, 4 Ac), 4.79 (bs, 1 H, H-1), 4.91 (d, 1 H, H-2'), 4.97 (bs, 1 H, H-1'), 5.10 (dd, 1 H, H-3'), 5.18 (dd, 1 H, H-4'), 5.75 (d, 1 H, H-2), 5.80 (dd, 1 H, H-4), 7.35-8.20 (m, 15 H, 3 C₆H₅); $J_{4,5} = 9.5$, $J_{4',5'} = 9.0$ Hz. Anal. Calcd for C₄₉H₅₈O₁₈ (934.95): C, 62.94; H, 6.25. Found: C, 62.88; H, 6.20.

Octyl 3-O-(α-D-mannopyranosyl)-β-D-mannopyranoside (29).—To a solution of disaccharide 28 (46.7 mg; 50 µmol) in dry MeOH (10 mL) was added NaOMe (16 mg, 0.3 mmol) and the mixture was boiled under reflux for 48 h. After cooling, the solution was neutralized with dry acidic resin (Amberlite IR 120, H⁺-form), filtered, and concentrated. Column chromatography of the crude product with CH₂Cl₂–MeOH gave 20.1 mg (88%) of 29 as an amorphous foam; $[\alpha]_D^{20} + 6^\circ$ (*c* 1.45, MeOH); ¹³C NMR (75.5 MHz, CD₃OD): δ 14.4 (CH₃), 23.7, 27.1, 30.4, 30.5, 30.7, and 33.0 (OCH₂(CH₂)₆CH₃), 62.8, and 63.1 (C-6,6'), 67.6 (OCH₂), 82.7 (C-3), 101.5 (C-1), 103.8 (C-1'). MS (FAB, Xe, 8 kV): *m/z* 455 [M⁺+1], 477 [M + Na⁺].

Octyl 4-O-acetyl-2-O-benzoyl-6-O-(2,3,4,6-tetra-O-

 $acetyl - \alpha - D - mannopyranosyl) - \beta - D - mannopyranoside$ (30).—A solution of disaccharide 27 (313 mg, 0.36 mmol) in EtOH (60 mL) and HOAc (10 mL) was hydrogenated over 10% palladium-carbon at room temperature for 2 h. The mixture was filtered, and the filtrate was concentrated to dryness to afford a residue which was eluted from a silica gel column with 7:3 CH_2Cl_2 -EtOAc. The eluate containing 30, upon evaporation gave 238 mg (86%) of a syrup; $[\alpha]_{\rm D}^{20}$ – 5.5° (c 1, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 0.84 (t, 3 H, CH₃), 1.17–1.55 (m, 12 H, 6 CH₂), 2.00, 2.02, 2.08, 2.15, and 2.17 (5 s, each 3 H, 5 Ac), 2.51 (bs, 1 H, OH), 3.53 (dt, 1 H, OCH₂), 3.64–4.32 (m, 7 H, H-5,6a,6b,5',6'a,6'b, and OCH₂), 3.72 (dd, 1 H, H-3), 4.72 (d, 1 H, H-1), 4.86 (d, 1 H, H-1'), 5.08 (t, 1 H, H-4), 5.27-5.38 (m, 3 H, H-2',3',4'), 5.63 (dd, 1 H, H-2), 7.45–8.10 (m, 5 H, C_6H_5); $J_{1,2} = 1.0, \ J_{2,3} \approx 2.9, \ J_{3,4} = J_{4,5} = 9.3, \ J_{1',2'} = 1.3 \text{ Hz}.$ MS (FD/15 mA): m/z 768 [M⁺], 769 [M⁺+1].

Octyl 6-O-(α-D-mannopyranosyl)-β-D-mannopyranoside (**31**).—To a solution of **30** (127 mg, 0.17 mmol) in dry MeOH (13 mL) was added a catalytic amount of sodium methoxide (pH 8). The mixture was kept at room temperature overnight, neutralized with dry acidic resin (Amberlite IR 120, H⁺-form), filtered and concentrated. Column chromatography of the residue with 7:3 CH₂Cl₂-MeOH gave 71 mg (95%) of **31** as a white foam; $[\alpha]_D^{20} + 4.5^\circ$ (*c* 0.19, MeOH); ¹³C NMR (75.5 MHz, CD₃OD): δ 14.4 (CH₃), 23.6, 27.1, 30.7, 30.5, 30.7, and 32.9 (6 CH₂), 62.8 (C-6'), 67.3 (OCH₂), 70.7 (C-6), 101.3 (C-1'), 101.8 (C-1). MS (FAB, Xe, 8 kV): *m/z* 455 [M⁺+ 1], 477 [M + Na⁺].

Octyl 4-O-acetyl-2-O-benzoyl-3,6-di-O-(2,3,4,6-tetra -O-acetyl- α -D-mannopyranosyl)- β -D-mannopyranoside (32).—A solution of 30 (140 mg, 0.18 mmol) and 2,3,4,6-tetra-O-acetyl- α -D-mannopyranosyl trichloroacetimidate [24] (25; 220 mg, 0.45 mmol) in CH_2Cl_2 (5 mL), containing molecular sieves (4 Å, 1 g) was stirred under argon for 30 min at room temperature whereupon trimethylsilyl triflate (80 μ L, 0.45 mmol) was added dropwise. The mixture was stirred for 45 min at room temperature and quenched by the addition of pyridine (3 mL). Dilution with CH_2Cl_2 (20 mL), filtration through Celite, and successive washing with saturated aq NaHCO₃ (2×5 mL), and water $(2 \times 5 \text{ mL})$ gave upon drying (Na_2SO_4) and removal of the solvent in vacuo a syrup which was purified by elution from a silica gel column with 7:3 CH₂Cl₂-EtOAc. The eluate containing 32 upon evaporation in vacuo, afforded 145 mg (73%) as a colorless syrup; $[\alpha]_{\rm D}^{20} - 2.1^{\circ}$ (c 1.1, CHCl₃); ¹H NMR (300 MHz, CDCl₃): δ 0.84 (t, 3 H, CH₃), 1.17–1.52 (m, 12 H, 6 CH₂), 1.94, 1.99, 2.01, 2.02, 2.08, 2.11, 2.14, 2.16, and 2.17 (9 s, each 3 H, 9 Ac), 4.00 (dd, 1 H, H-3), 4.70 (s, 1 H, H-1), 4.83 (d, 1 H, H-1'), 5.01 (d, 1 H, H-1''), 5.11 (dd, 1 H, H-3'), 5.21 (dd, 1 H, H-4), 5.70 (d, 1 H, H-2), 7.43–8.07 (m, 5 H, C₆H₅); $J_{2,3} = 3.0$, $J_{3,4} = 9.4$, $J_{4,5} = 9.6$, $J_{1',2'} = 1.5$, $J_{2',3'} = 2.9$, $J_{3',4'} = 10.1$, $J_{1',2''} = 2.1$ Hz; ¹³C NMR (75.5 MHz, CDCl₃): δ 14.2 (CH₃), 20.7–21.0 (COCH₃), 22.7, 26.0, 29.3, 29.4, 29.5, and 31.8 (CH₂), 70.0 (OCH₂), 70.9 (C-2), 77.7 (C-3), 97.3 (C-1'), 98.8 (C-1), 99.4 (C-1''), 128.6– 133.3 (C₆H₅), 166.2 (COC₆H₅), 169.4, 169.8, 169.9, 170.2, 170.3, 170.7, 170.8 (9 COCH₃); $J_{C-1', H-1'} = 173.4$, $J_{C-1'', H-1''} = 173.0$, J_{C-1} , H-1 = 157.0 Hz. MS (FD/20 mA): m/z 1099 [M⁺], 1100 [M⁺ + 1].

Octyl 3, 6 - di - O - (α - D - mannopyranosyl) - β - D mannopyranoside (8).—To a solution of 32 (110 mg, 1 mmol) in dry MeOH (15 mL) was added NaOMe (20 mg, 0.37 mmol) and the mixture was boiled under reflux for 48 h. After cooling the solution was neutralized with acidic resin (Amberlite IR 120, H⁺form), filtered and concentrated. The residue was purified by means of column chromatography with 2:1:1 1-butanol–MeOH–water, giving 52 mg (84%) of amorphous 8; [α]²⁰_D + 23.7° (*c* 1.74, CHCl₃); ¹³C NMR (75.5 MHz, CD₃OD): δ 14.4 (CH₃), 23.7, 27.1, 30.4, 30.6, 30.7, and 33.0 (6 CH₂), 62.8, and 63.0 (C-6',6''), 67.2 (OCH₂), 70.8 (C-6), 82.8 (C-3), 101.3 (C-1''), 101.6 (C-1), 103.9 (C-1'). MS (FAB, Xe, 8 kV): *m/z* 617 [M⁺ + 1], 639 [M + Na⁺].

Acknowledgements

Support of this work by the Volkswagen–Stiftung, Hannover (fellowship to Z.S.) and the Fonds der Chemischen Industrie is gratefully acknowledged.

References

- Reviews: (a) E. Kaji and F.W. Lichtenthaler, *Trends Glycosci. Glycotechnol.*, 5 (1993) 121–142; (b) F. Barresi and O. Hindsgaul, in S.H. Khan, R.A. O'Neill (Eds.), *Modern Methods in Carbohydrate Synthesis*, Harwood Acad. Publ., Amsterdam, 1996, pp. 251–276.
- [2] F. Barresi and O. Hindsgaul, J. Am. Chem. Soc., 113 (1991) 9376–9377; Synlett, (1992) 759–761; Can. J. Chem., 72 (1994) 1447–1465.

- [3] G. Stork and G. Kim, J. Am. Chem. Soc., 114 (1992) 1087–1088; G. Stork, J.J. La Clair, *ibid.*, 118 (1996) 247–248.
- [4] Y. Ito and T. Ogawa, Angew. Chem., 106 (1994) 1843–1845; Angew. Chem., Int. Ed. Engl., 33 (1994) 1765–1767; A. Dan, Y. Ito, and T. Ogawa, J. Org. Chem., 60 (1995) 4680–4681.
- [5] F.W. Lichtenthaler, E. Cuny, and S. Weprek, Angew. Chem., 95 (1983) 906–907; Angew. Chem. Int. Ed. Engl., 22 (1983) 891–892.
- [6] F.W. Lichtenthaler, E. Kaji, and S. Weprek, J. Org. Chem., 50 (1985) 3505-3515.
- [7] F.W. Lichtenthaler and E. Kaji, *Liebigs Ann. Chem.*, (1985) 1659–1668.
- [8] F.W. Lichtenthaler, U. Kläres, M. Lergenmüller, and S. Schwidetzky, Synthesis, (1992), 179–184.
- [9] F.W. Lichtenthaler and T. Schneider-Adams, J. Org. Chem., 59 (1994) 6728–6734.
- [10] F.W. Lichtenthaler, T. Schneider-Adams, and S. Immel, J. Org. Chem., 59 (1994) 6735–6738.
- [11] A. Fürstner and I. Konetzki, *Tetrahedron*, 52 (1996) 15071–15078.
- [12] P. Jarglis and F.W. Lichtenthaler, *Tetrahedron Lett.*, 21 (1980) 1425–1428; *Angew. Chem.*, 94 (1982) 140–141; *Angew. Chem.*, Int. Ed. Engl., 21 (1982) 141–142; *Angew. Chem. Suppl.*, (1982) 175–183.
- [13] F.W. Lichtenthaler and P. Jarglis, Angew. Chem., 94 (1982) 643; Angew. Chem., Int. Ed. Engl., 21 (1982) 625; Angew. Chem. Suppl., (1982) 1449–1459; F.W. Lichtenthaler, P. Jarglis, and W. Hempe, Liebigs Ann. Chem., (1983) 1959–1972.
- [14] E. Kaji, F.W. Lichtenthaler, T. Nishino, Y. Yamane, and S. Zen, Bull. Chem. Soc. Jpn., 61 (1988) 1291– 1297.
- [15] E. Kaji, F.W. Lichtenthaler, Y. Osa, K. Takahashi, and S. Zen, *Chem. Lett.*, (1992) 707–710; *Bull. Chem. Soc. Jpn.*, 68 (1995) 2401–2408.
- [16] E. Kaji and F.W. Lichtenthaler, J. Carbohydr. Chem., 14 (1995) 791–803.
- [17] E. Kaji, Y. Osa, K. Takahashi, M. Hirooka, S. Zen, and F.W. Lichtenthaler, *Bull. Chem. Soc. Jpn.*, 67 (1994) 1130–1140.
- [18] G.W.J. Fleet and D.R. Witty, *Tetrahedron Asymmetry*, (1990), 119–136.
- [19] D. Charon and L. Szabó, J. Chem. Soc. Perkin Trans. I, (1980), 1971–1977.
- [20] C.D. Warren, C. Augé, M.L. Laver, S. Suzuki, D. Power, and R.W. Jeanloz, *Carbohydr. Res.*, 82 (1980) 71–83; C. Augé, D.D. Warren, R.W. Jeanloz, M. Kiso, and L. Anderson, *ibid.*, 82 (1980) 85–95.
- [21] K. Freudenberg, H. von Hochstetter, and H. Engels, Ber. Dtsch. Chem. Ges., 58 (1925) 666–671.
- [22] B.H. Koeppen, Carbohydr. Res., 24 (1972) 154-158.
- [23] M. Bertolini and C.P.J. Glaudemans, *Carbohydr. Res.*, 15 (1970) 263–267.
- [24] J. Kerékgyártó, J.P. Kamerling, J.B. Bouwstra, J.F.G. Vliegenthart, and A. Lipták, *Carbohydr. Res.*, 186 (1989) 51–62.